Published in Skeletal Radiol on June 09, 2007
Epiphyseal presentation of non-Hodgkin's lymphoma of bone in two pediatric patients--one with primary lymphoma of bone. Skeletal Radiol (2014) 0.78
Nuclear factor-κB activation in primary lymphoma of bone. Virchows Arch (2013) 0.77
Primary bone lymphoma of radius and tibia: A case report and review of literature. Medicine (Baltimore) (2017) 0.75
Thigh pain in an 18-year-old man. Clin Orthop Relat Res (2014) 0.75
Primary alveolar soft part sarcoma of the right femur and primary lymphoma of the left femur: A case report and literature review. Oncol Lett (2015) 0.75
Sclerotic changes on plain X-ray led to early diagnosis and successful treatment of primary lymphoma of iliac bone. J Res Med Sci (2015) 0.75
Primary malignant lymphoma of the talus: A case report and review of the literature. Mol Clin Oncol (2017) 0.75
Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer (2006) 2.09
Imaging features of primary lymphoma of bone. AJR Am J Roentgenol (1999) 1.84
Primary non-Hodgkin's lymphoma of bone. A clinicopathologic study. Cancer (1994) 1.40
Primary bone lymphoma: radiographic-MR imaging correlation. Radiographics (2003) 1.35
Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia (1999) 1.32
Primary lymphoma of bone: the use of MRI in pretreatment evaluation. Am J Clin Oncol (1989) 1.20
Oncologic outcomes of primary lymphoma of bone in adults. Clin Orthop Relat Res (2003) 1.09
Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II. Int J Radiat Oncol Biol Phys (2004) 1.05
Primary bone lymphoma in 24 patients treated between 1955 and 1999. Clin Orthop Relat Res (2002) 1.00
Non-Hodgkin's lymphoma in bone. Pathologic and radiologic features with clinical correlates. Cancer (1987) 0.99
The management of primary lymphoma of bone. Radiother Oncol (1987) 0.96
MRI of primary lymphoma of bone: cortical disorder as a criterion for differential diagnosis. J Magn Reson Imaging (1999) 0.93
Primary non-Hodgkin's lymphoma of bone. Semin Oncol (1999) 0.93
Primary lymphoma of bone. Correlation of magnetic resonance imaging features with cytokine production by tumor cells. Cancer (1995) 0.92
MRI in the diagnosis of primary lymphoma of bone: correlation with histopathology. J Comput Assist Tomogr (1992) 0.86
Malignant lymphomas with primary bone manifestation. Pathol Res Pract (1987) 0.84
Primary lymphoma of bone: a clinico-pathological review and analysis of prognostic factors. Leuk Lymphoma (2004) 0.82
Primary periosteal lymphoma: an unusual presentation of non-Hodgkin's lymphoma with radiographic, MR imaging, and pathologic correlation. Skeletal Radiol (2003) 0.78
Primary lymphoma of bone: MRI and CT characteristics during and after successful treatment. AJR Am J Roentgenol (2005) 0.76
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
The clinical approach towards chondrosarcoma. Oncologist (2008) 3.01
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol (2010) 2.17
Technical considerations in CT-guided radiofrequency thermal ablation of osteoid osteoma: tricks of the trade. AJR Am J Roentgenol (2002) 2.10
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol (2012) 2.02
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer (2005) 2.01
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol (2009) 1.96
Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol (2003) 1.85
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology (2010) 1.78
Lymphatics and bone. Hum Pathol (2007) 1.76
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer (2010) 1.63
Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol (2009) 1.63
A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer (2010) 1.56
Detection of partial-thickness supraspinatus tendon tears: is a single direct MR arthrography series in ABER position as accurate as conventional MR arthrography? Skeletal Radiol (2009) 1.54
Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist (2011) 1.54
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer (2010) 1.50
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46
Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer (2011) 1.44
The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol (2010) 1.43
The Bt-DUX: development of a subjective measure of health-related quality of life in patients who underwent surgery for lower extremity malignant bone tumor. Pediatr Blood Cancer (2009) 1.42
The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst (2007) 1.37
Proximal humerus reconstruction after tumour resection: biological versus endoprosthetic reconstruction. Int Orthop (2010) 1.34
EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res (2007) 1.33
Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging (2002) 1.33
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest (2011) 1.32
Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene (2004) 1.32
The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res (2009) 1.31
Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology (2004) 1.31
Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol (2005) 1.30
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol (2010) 1.29
Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev (2010) 1.28
Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer (2010) 1.27
Genome-wide analysis of Ollier disease: Is it all in the genes? Orphanet J Rare Dis (2011) 1.24
Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells (2011) 1.23
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol (2009) 1.23
Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res (2009) 1.22
Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol (2006) 1.21
Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity. Arthritis Rheum (2007) 1.20
Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn (2002) 1.19
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res (2005) 1.18
No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer (2009) 1.18
Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Hum Mutat (2004) 1.17
Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol (2005) 1.16
Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin. Hum Pathol (2005) 1.15
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res (2009) 1.14
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One (2012) 1.13
Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma. J Pathol (2014) 1.12
Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res (2009) 1.12
Value of dynamic contrast-enhanced MR imaging in diagnosing and classifying peripheral vascular malformations. AJR Am J Roentgenol (2002) 1.11
Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol (2009) 1.11
Imaging mass spectrometry statistical analysis. J Proteomics (2012) 1.11
Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer (2012) 1.11
Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch (2009) 1.10
Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med (2003) 1.10
Distinct histological features characterize primary angiosarcoma of bone. Histopathology (2011) 1.10
Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol (2004) 1.10
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer Res (2012) 1.09
Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol (2009) 1.09
No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas. Am J Pathol (2010) 1.08
Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity. J Pathol (2010) 1.08
Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol (2004) 1.08
Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res (2011) 1.07
Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med (2005) 1.07
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer (2011) 1.06
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer (2011) 1.06
Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer (2010) 1.06
Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma. Lab Invest (2010) 1.05
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol (2009) 1.05
Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro. J Cell Mol Med (2008) 1.04
Mutation screening of EXT1 and EXT2 by direct sequence analysis and MLPA in patients with multiple osteochondromas: splice site mutations and exonic deletions account for more than half of the mutations. Eur J Hum Genet (2005) 1.04
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer (2013) 1.03